(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
8 May 2008 (08.05.2008)

PCT

(10) International Publication Number
WO 2008/054465 A2

(51) International Patent Classification:
A61K 38/17 (2006.01)

(21) International Application Number:
PCT/US2007/005668

(22) International Filing Date: 6 March 2007 (06.03.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/780,825	10 March 2006 (10.03.2006)	US
60/781,367	13 March 2006 (13.03.2006)	US
60/828,723	9 October 2006 (09.10.2006)	US
60/899,035	2 February 2007 (02.02.2007)	US

(71) Applicant *(for all designated States except US)*: **IMMUNEREGEN BIOSCIENCES, INC.** [US/US]; 4021 N. 75th Street, Suite 201, Scottsdale, AZ 85251 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **SIEGEL, Hal** [US/US]; 7111 E. McDonald Drive, Paradise Valley, AZ 85253-5406 (US). **KALNS, John** [US/US]; 13302 Langtry Street, San Antonio, TX 78248 (US).

(74) Agent: **INSOGNA, Anthony, M.**; Jones Day, 222 East 41st Street, New-York, NY 10017-6702 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished upon receipt of that report*

WO 2008/054465 A2

(54) **Title:** METHOD TO REDUCE THE RISK AND/OR SEVERITY OF ANTHRAX INFECTION

(57) **Abstract:** Neuropeptides are used to treat mammals who have been exposed to or who are suspected of having been exposed to spores of Bacillus anthracis. The treatment provides a dose- dependent protection from the lethal consequences of infections.